{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:33:39Z","timestamp":1775680419713,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T23:51:17Z","timestamp":1591228277000},"page":"5085-5088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?"],"prefix":"10.1016","volume":"38","author":[{"given":"G. Owen","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarence C.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Savulescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teck Chuan","family":"Voo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.007_b0005","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa152","article-title":"Human challenge studies to accelerate coronavirus vaccine licensure","author":"Eyal","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.007_b0010","unstructured":"Roland D. Wanted: People willing to get sick to find coronavirus vaccine. The Wall Street Journal, https:\/\/www.wsj.com\/articles\/wanted-people-willing-to-get-sick-to-find-coronavirus-vaccine-11584615600; 2020 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0015","unstructured":"Whipple T. Loosen rules \u2018to speed up hunt for coronavirus vaccine\u2019. The Times, https:\/\/www.thetimes.co.uk\/article\/loosen-rules-to-speed-up-hunt-for-coronavirus-vaccine-vv5fhczm7; 2020 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/phe\/phv026","article-title":"Ethical criteria for human challenge studies in infectious diseases","volume":"9","author":"Bambery","year":"2016","journal-title":"Public Health Ethics"},{"key":"10.1016\/j.vaccine.2020.06.007_b0025","article-title":"Studies that intentionally infect people with disease-causing bugs are on the rise","author":"Cohen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.06.007_b0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2016.05.013","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","volume":"49","author":"Balasingam","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.007_b0035","unstructured":"Thompson SA. How long will a vaccine really take? The New York Times, https:\/\/www.nytimes.com\/interactive\/2020\/04\/30\/opinion\/coronavirus-covid-vaccine.html; 2020 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8863","article-title":"Emergency use authorization of Remdesivir: the need for a transparent distribution process","author":"Ison","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.06.007_b0045","unstructured":"Macklin R. Human challenge studies for a COVID-1Vaccine: ethical quandaries. Albert Einstein College of Medicine, the doctor's tablet blog, http:\/\/blogs.einstein.yu.edu\/human-challenge-studies-for-a-covid-19-vaccine-ethical-quandaries\/; 2020 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0050","unstructured":"Johns Hopkins University of Medicine. Maps and trends: mortality analyses, https:\/\/coronavirus.jhu.edu\/data\/mortality; 2020 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0055","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","author":"Salje","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.06.007_b0060","doi-asserted-by":"crossref","unstructured":"Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano E, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. medRxiv, https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/30\/2020.04.14.20062463.full.pdf; 2020 [accessed 20 May 2020].","DOI":"10.1101\/2020.04.14.20062463"},{"key":"10.1016\/j.vaccine.2020.06.007_b0065","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8279","article-title":"Seroprevalence of SARS-CoV-2\u2013specific antibodies among adults in Los Angeles County, California, on April 10\u201311, 2020","author":"Sood","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.06.007_b0070","unstructured":"World Health Organization. Global status report on road safety 2015, table A2, https:\/\/www.who.int\/violence_injury_prevention\/road_safety_status\/2015\/GSRRS2015_data\/en\/; 2015 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0075","article-title":"Supplementary materials for ethics of controlled human infection to study COVID-19","author":"Seema","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.06.007_b0080","unstructured":"Shah SK, Kimmelman J, Lyerly AD, Lynchet HF, Miller FG, Palacios R, et al. Ethical considerations for Zika virus human challenge trials. https:\/\/www.niaid.nih.gov\/sites\/default\/files\/EthicsZikaHumanChallengeStudiesReport2017.pdf; 2017 [accessed 20 May 2020]."},{"key":"10.1016\/j.vaccine.2020.06.007_b0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2018.12.040","article-title":"Demonstrating vaccine effectiveness during a waning epidemic: a WHO\/NIH meeting report on approaches to development and licensure of Zika vaccine candidates","volume":"37","author":"Vannice","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.007_b0090","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for health-related research involving humans. 4th ed. Geneva; 2016."},{"key":"10.1016\/j.vaccine.2020.06.007_b0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jlb\/lsv006","article-title":"Science wars\u2014how much risk should soldiers be exposed to in military experimentation?","volume":"2","author":"Savulescu","year":"2015","journal-title":"J Law Biosci"},{"key":"10.1016\/j.vaccine.2020.06.007_b0100","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMsb2005114","article-title":"Fair allocation of scarce medical resources in the time of Covid-19","author":"Emanuel","year":"2020","journal-title":"NEJM"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:44:25Z","timestamp":1759401865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20307684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20307684"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}